## REGN: Regeneron Pharmaceuticals, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.1% below STRENGTH zone (3.0-6.0%); PEG 1.55 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.6% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($738.82)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 6
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Consensus Rating of "Moderate Buy" by Brokerages**
- Source: MarketBeat | 20251229T070859 | Somewhat-Bullish | Relevance: 100%
- Regeneron Pharmaceuticals (NASDAQ:REGN) has received a "Moderate Buy" consensus rating from 27 analysts, with an average 12-month price target of $779.45. The company recently exceeded quarterly earnings and revenue expectations, and its stock is trading near its 1-year high. Insider transactions show recent share sales by a VP and a director, though insiders still own 7.02% of the stock.

**2. TB Alternative Assets Ltd. Increases Position in Regeneron Pharmaceuticals, Inc. $REGN**
- Source: MarketBeat | 20251228T114850 | Bullish | Relevance: 100%
- TB Alternative Assets Ltd. significantly increased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 174.0% in Q3, now holding 8,652 shares valued at $4.865 million. This makes Regeneron its 27th-largest position. The company also reported strong quarterly earnings, topping analyst estimates, and announced a quarterly dividend.

**3. Bellecapital International Ltd. Buys 2,276 Shares of Regeneron Pharmaceuticals, Inc. $REGN**
- Source: MarketBeat | 20251228T080841 | Bullish | Relevance: 100%
- Bellecapital International Ltd. increased its holdings in Regeneron Pharmaceuticals (NASDAQ:REGN) by 8.9%, purchasing 2,276 shares to own a total of 27,779 shares valued at $15.62 million. This move makes Regeneron its 16th largest holding, comprising about 2.5% of its portfolio. Other institutions like Dodge & Cox and Norges Bank also significantly increased their stakes, bringing institutional ownership to approximately 83.3%.

**4. Amgen Inc.: How a Biotech Veteran Is Rebuilding Its Flagship Pipeline**
- Source: AD HOC NEWS | 20251230T092051 | Somewhat-Bullish | Relevance: 71%
- Amgen Inc. is transforming its growth strategy by shifting focus from mature blockbusters to innovative biologics, biosimilars, and new weight-loss drugs. This evolution aims to build a modular biotech platform with broad therapeutic coverage and multiple revenue streams. The company's future growth hinges on the success of these new assets, particularly MariTide in the obesity market.

**5. AbbVie (NYSE:ABBV) - Stock Analysis**
- Source: Simply Wall Street | 20251228T110756 | Neutral | Relevance: 63%
- This report provides a comprehensive stock analysis of AbbVie (NYSE:ABBV), highlighting its strong performance in immunology and neuroscience. The company is trading at a discount to its estimated fair value with projected earnings growth, but faces risks from large one-off items, high debt, and a dividend not fully covered by earnings. AbbVie's strategic pipeline development and operational efficiency are key factors for sustained profitability.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 4, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-12 | Morgan Stanley | $768 | $767 | +0% |
| 2025-12-10 | Wells Fargo | $745 | $700 | +6% |
| 2025-12-04 | Canaccord Genui | $1057 | $850 | +24% |
| 2025-12-04 | BMO Capital | $850 | $725 | +17% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-12 | Morgan Stanley | main | Equal-Weight |
| 2025-12-10 | Wells Fargo | main | Equal-Weight |
| 2025-12-04 | Canaccord Genui | main | Buy |
| 2025-12-04 | BMO Capital | main | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 9 ($97.67M) |
| Sells | 15 ($32.83M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 8.8% (-4.0%)
- Blackrock Inc.: 8.6% (-4.7%)
- JPMORGAN CHASE & CO: 7.9% (+106.7%)
- State Street Corpora: 4.5% (-2.9%)
- Dodge & Cox Inc.: 4.4% (+18.9%)

### Key Risks

1. Heavy insider selling: $33M sold (15 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 4 raises (avg +12%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.55 elevated, pricing in significant growth expectations. Quality metrics strong (margin 32%). Balance sheet: strong liquidity (4.1x), low leverage (D/E 0.30), $1.4B free cash flow. Analyst sentiment positive (4 raises, avg +12%). Insider buying signal ($97.7M), management confidence. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $82.0B |
| Beta | 0.37 |
| 52W Range | $476.49 - $792.77 |
| Short Interest | 2.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.55 |
| Forward P/E | 20.0 |
| Current P/E | 17.9 |
| YoY Growth | -10.3% |
| EPS Direction | RISING |

### Technicals

MRS_10 deteriorating from 2.7% to 0.1% (-2.6% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 2.9pp (needs >3.0% for momentum thesis). MRS_5 (-0.5%) diverging from MRS_10 - short-term weakness emerging. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: -SLL (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.09% (CS: 63) | Neutral |
| RSI_14 | 62.1 | Neutral |
| MACD Histogram | 0.07 | Bullish |
| vs SMA20 | 1.034x | Above |
| vs SMA50 | 1.100x | Above |
| vs SMA200 | 1.283x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $773.94
- **Stop Loss:** $738.82 (4.5% risk)
- **Target:** $809.06 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 37
- **Position Value:** $28,635.78
- **Portfolio %:** 28.64%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with balanced risk signals and moderate market participation. VIX at 14.33 indicates calm conditions, while positive yield curve (+59bps) and stable economic data support continued expansion. Year-end positioning and Fed uncertainty create near-term caution, but no systemic risks evident.*

### Earnings

**Next:** 2026-02-03 (Est: $10.77)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $9.64 | $11.83 | +22.7% |
| 2025Q2 | $8.44 | $12.89 | +52.7% |
| 2025Q1 | $8.48 | $8.22 | -3.0% |
| 2024Q4 | $11.19 | $12.07 | +7.8% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*